EU gives Devax bifurcation stent system nod of approval
The European Union (EU) has granted a CE Mark of approval to Devax for the marketing and distribution of its Axxess Biolimus A9-eluting coronary bifurcation stent system.

The Axxess system, which is a proprietary self-expanding nitinol stent, is used to treat coronary and vascular bifurcation lesions.

According to Irvine, Calif.-based company, it has entered into an agreement with Biosensors International for the stent's bioabsorable coating and the drug Biolimus A9.